Patents by Inventor Werner Frantsits

Werner Frantsits has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10265397
    Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: April 23, 2019
    Assignee: SANOCHEMIA PHARMAZEUTIKA AG
    Inventors: Stefan Welzig, Gregor Medinger, Beate Kálz, József Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
  • Patent number: 10201609
    Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: February 12, 2019
    Assignee: SANOCHEMIA PHARMAZEUTIKA AG
    Inventors: Stefan Welzig, Gregor Medinger, Beate Kälz, József Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
  • Patent number: 10143751
    Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: December 4, 2018
    Assignee: SANOCHEMIA PHARMAZEUTIKA AG
    Inventors: Stefan Welzig, Gregor Medinger, Beate Kalz, Jozsef Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
  • Publication number: 20180055934
    Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.
    Type: Application
    Filed: November 7, 2017
    Publication date: March 1, 2018
    Inventors: Stefan WELZIG, Gregor MEDINGER, Beate KÄLZ, József GUNGL, Klaus GERDES, Werner FRANTSITS, Christina ABRAHAMSBERG
  • Publication number: 20180055935
    Abstract: Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.
    Type: Application
    Filed: November 7, 2017
    Publication date: March 1, 2018
    Inventors: Stefan WELZIG, Gregor MEDINGER, Beate KÄLZ, József GUNGL, Klaus GERDES, Werner FRANTSITS, Christina ABRAHAMSBERG
  • Patent number: 9775900
    Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: October 3, 2017
    Assignee: SANOCHEMIA PHARMAZEUTIKA AG
    Inventors: Stefan Welzig, Beate Kälz, József Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
  • Publication number: 20170196976
    Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.
    Type: Application
    Filed: March 27, 2017
    Publication date: July 13, 2017
    Inventors: Stefan WELZIG, Beate KÄLZ, József GUNGL, Klaus GERDES, Werner FRANTSITS, Christina ABRAHAMSBERG
  • Patent number: 9629932
    Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: April 25, 2017
    Assignee: SANOCHEMIA PHARMAZEUTIKA AG
    Inventors: Stefan Welzig, Beate Kalz, Jozsef Gungl, Klaus Gerdes, Werner Frantsits, Christina Abrahamsberg
  • Publication number: 20170087256
    Abstract: In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.
    Type: Application
    Filed: October 8, 2015
    Publication date: March 30, 2017
    Inventors: Stefan WELZIG, Beate KALZ, Jozsef GUNGL, Klaus GERDES, Werner FRANTSITS, Christina ABRAHAMSBERG
  • Publication number: 20170087249
    Abstract: A treatment of cancer, such as, for example, bladder cancer, uses a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.
    Type: Application
    Filed: October 8, 2015
    Publication date: March 30, 2017
    Inventors: Stefan WELZIG, Gregor MEDINGER, Beate KALZ, Jozsef GUNGL, Klaus GERDES, Werner FRANTSITS, Christina ABRAHAMSBERG
  • Publication number: 20080226713
    Abstract: The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a tablet or granule, a specific release of active substance can be adjusted which is matched to the special genotype in the metabolisation of tolperisone. At the same time, as a result of the very uniform and persistent release of tolperisone, the in vivo inversion of enantiomerically pure tolperisone that is known from the art can be adjusted in favour of the R(?)tolperisone which is prominent in muscle-relaxing therapy.
    Type: Application
    Filed: March 7, 2005
    Publication date: September 18, 2008
    Inventors: Angelika Bodenteich, Eberhard Pirich, Josef Bockmann, Werner Frantsits
  • Publication number: 20080031935
    Abstract: The invention relates to a pharmaceutical composition based on an active ingredient that is enclosed in liposomes for topical, transdermal application. The interior of said liposomes comprises an acidic, aqueous medium containing at least one cholinesterase inhibitor, preferably from the group containing donepezil, rivastigmine, galantamine, physostigmine, heptylphysostigmine, phenserine, tolserine, cymserine, thiatolserine, thiacymserine, neostigmine, huperzine, tacrine, metrifonate and dichlorvos, or an enantiomer or derivative of at least one of said compounds. In addition, the invention relates to a method for producing said composition, optionally in a sterile form and also to the use of the liposomes charged with the active ingredient in various galenic formulations for topical, transdermal application with a depot effect in the epidermis, for the prophylaxis and/or treatment of cutaneous neuropathic pain or the loss of cutaneous sensory function as a result of neuropathy.
    Type: Application
    Filed: April 21, 2005
    Publication date: February 7, 2008
    Inventors: Angelika Bodenteich, Josef Bockmann, Werner Frantsits, Eberhard Pirich, Andreas Wagner, Karola Vorauer-Uhl
  • Publication number: 20070249673
    Abstract: The present invention is directed to methods of administering tolperisone (2,4?-dimethyl-3-piperidinopropiophenone; 1-propanone, 2-methyl-1-(4-methylphenyl)-3-(-piperidinyl)), and kits comprising the same.
    Type: Application
    Filed: April 20, 2007
    Publication date: October 25, 2007
    Inventors: Angelika Bodenteich, Josef Bockmann, Werner Frantsits
  • Publication number: 20060198888
    Abstract: The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a tablet or granule, a specific release of active substance can be adjusted which is matched to the special genotype in the metabolisation of tolperisone. At the same time, as a result of the very uniform and persistent release of tolperisone, the in-vivo inversion of enantiomerically pure tolperisone that is known from the art can be adjusted in favour of the R(?) tolperisone which is prominent in muscle-relaxing therapy.
    Type: Application
    Filed: February 16, 2006
    Publication date: September 7, 2006
    Inventors: Angelika Bodenteich, Eberhard Pirich, Josef Bockmann, Werner Frantsits
  • Publication number: 20060111341
    Abstract: The invention relates to the use of galanthamine and the cholinergically active derivatives thereof in the production of medicaments for preventive treatment of postoperative delirium and/or subsyndronal postoperative delirium. Galanthamine, the galathamine derivative(4aS,6R,8aS)-6-hydroxy-3-methoxy-11-methyl-4a,5,9,10-tetrahydro-6H-benzofuro[3a,3,2-ef][2]benzazepinium bromide and analogous salts, hydrates or solvates are advantageously suited for use according to the invention.
    Type: Application
    Filed: July 12, 2004
    Publication date: May 25, 2006
    Inventors: Angelika Bodenteich, Werner Frantsits, Eberhard Pirich, Laszlo Czollner
  • Publication number: 20050196451
    Abstract: The invention relates to a tolperisone-containing pharmaceutical preparation with controllable active-substance release for oral administration, characterised in that the active substance tolperisone and/or a pharmaceutical salt thereof is embedded in a pharmaceutically compatible material. By selecting the pharmaceutically compatible materials in the preparation and accordingly in the coating of a tablet or granule, a specific release of active substance can be adjusted which is matched to the special genotype in the metabolisation of tolperisone. At the same time, as a result of the very uniform and persistent release of tolperisone, the in-vivo inversion of enantiomerically pure tolperisone that is known from the art can be adjusted in favour of the R(?) tolperisone which is prominent in muscle-relaxing therapy.
    Type: Application
    Filed: September 2, 2004
    Publication date: September 8, 2005
    Inventors: Angelika Bodenteich, Eberhard Pirich, Josef Bockmann, Werner Frantsits
  • Patent number: 6500455
    Abstract: A pharmaceutical preparation containing Tolperison or a salt thereof as an active ingredient in the form of a racemic mixture which can be a 50/50/-racemat or a racemat with the perponderant content of the (−) -isomer of Tolperison. The pharmaceutical preparation is formulated as a solid or liquid medicament for oral administration. The active ingredient Tolperison that is present as 50/50-racemat or as racemat with a preponderant content of the (−)-isomer or the (+)-isomer is liberated from the preparation in the human body in a delayed manner and preferably in the intestinal canal.
    Type: Grant
    Filed: October 1, 2001
    Date of Patent: December 31, 2002
    Assignee: Sanochemia Pharmazeutika
    Inventor: Werner Frantsits